Douglas Harrington, MD


Douglas Harrington, MD

Dr. Harrington is the Chairman and Chief Medical and Science Officer of Smart Health Diagnostics Company, a developer of precision diagnostics that address unmet clinical needs in vascular, metabolic, and oncological diseases using unique evolutionary computational technology. The technology has been successfully applied to 135 projects across 34 diseases. He is the developer of the Smart Vascular Dx Test (formerly PULS Cardiac Test), a breakthrough blood test for the detection of the leading cause of heart attacks. Dr. Harrington serves as Medical Director for the wholly-owned Native American Tshimakain Creek Cardiometabolic Laboratory in Spokane, WA. He has over 35 years of experience in the development of diagnostic technologies and has taken over 200 academic discoveries into clinical use. Dr Harrington is also a Senor Medical Reviewer with McKesson/ Change Healthcare and serves as Chief Medical Officer for Oncocyte, and Oncology Diagnostics Company. Dr. Harrington was a member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University. He co-founded one of the first clinical molecular biology laboratories in the US with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage. He is a member of Phi Betta Kappa and was a Clinical Professor of Pathology at the USC Keck School of Medicine for 15 years. Dr. Harrington received his BA in molecular biology and his MD from the University of Colorado Health Sciences Center, and is board-certified in hematology, anatomic, and clinical pathology, and is a Fellow of the American Society of Preventive Cardiology.